Cost-effectiveness of prevention program for type 2 diabetes mellitus in high risk patients in the Republic of Srpska, Bosnia and Herzegovina

被引:0
|
作者
Grujic-Vujmilovic, Dragana [1 ,2 ]
Veljkovic, Kristina [3 ]
Gavric, Zivana [1 ,2 ]
Popovic-Pejicic, Snjezana [4 ,5 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Social Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[2] Publ Hlth Inst Republ Srpska, Dept Social Med, Banja Luka, Republic of Srp, Bosnia & Herceg
[3] Univ Ljubljana, Fac Comp & Informat Sci, Lab Cryptog & Comp Secur, Vecna Pot 113, Ljubljana 1000, Slovenia
[4] Univ Banja Luka, Fac Med, Dept Internal Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[5] Univ Clin Ctr Republ Srpska, Banja Luka, Republic Of Srp, Bosnia & Herceg
关键词
Cost-effectiveness; Markov chain model; FINDRISC; prevention; impaired glucose tolerance; type 2 diabetes mellitus; GLUCOSE-TOLERANCE; CARDIOVASCULAR EVENTS; SCREENING-PROGRAM; UTILITY VALUES; MORTALITY; DISEASE; FOOT; LIFE; COMPLICATIONS; PROGRESSION;
D O I
10.1080/19932820.2024.2437226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Republic of Srpska (RS), as a part of the Western Balkans (WB) region, has a higher diabetes prevalence than the EU. This study aims to assess the cost-effectiveness of early treatment of high-risk patients with pre-diabetes and undiagnosed diabetes in our setting. We designed a Markov chain Monte Carlo (MCMC) model which reflects the current International Diabetes Federation (IDF) three-step plan for the prevention of T2DM in those at increased risk. The model captures the evolution of the disease in FINDRISC high-risk patients from normal glucose tolerance (NGT) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and then to T2DM and its complications. We developed two MCMC models, in order to follow the progression of the disease in high-risk cases, ie, when early treatment is undertaken or when it is not undertaken. The health costs and quality adjusted life years (QALY) were discounted at an annual rate of 3%. The key model parameters were varied in one-way and probabilistic sensitivity analysis. Early treatment resulted in increased life expectancy, postponement of the onset of diabetes and increased QALY for all patients. The discounted incremental cost-effectiveness-ratios (ICER) in NGT, IFG, IGT, and T2DM patients were -289.9, 9724.03, -1478.59 and 4084.67 <euro>. In high-risk IGT patients, ICER was the most favorable, being both a cost saving and QALY gaining, with the consistent results confirmed by the sensitivity analysis. The results recommend the acceptance of a new health policy of identifying IGT patients with the use of FINDRISC questionnaire and plasma glucose measurements; providing them with a lifestyle change program; and implementing intensive diabetes treatment, as their disease progresses. Our results are especially significant for the Western Balkan countries, since this was the first cost-effectiveness study of T2DM prevention in this region.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
  • [2] The incidence of type 1 diabetes in Republic of Srpska (Bosnia and Herzegovina) and Slovenia in the period 1998-2010
    Radosevic, Bojana
    Bukara-Radujkovic, Gordana
    Miljkovic, Vesna
    Pejicic, Snjezana
    Bratina, Natasa
    Battelino, Tadej
    PEDIATRIC DIABETES, 2013, 14 (04) : 273 - 279
  • [3] Cost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patients
    Maciel, Olga
    Vera, Zully
    Marin, Gustavo H.
    Morinigo, Macarena
    Maidana, Mabel
    Mastroianni, Patricia
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2018, 9 (05): : 1824 - 1829
  • [4] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ARGENTINA
    Rodriguez, L.
    Lew, D.
    VALUE IN HEALTH, 2020, 23 : S115 - S115
  • [5] Cost-effectiveness of primary prevention of type 2 diabetes
    Icks, A.
    Chernyak, N.
    Klein, A.
    Brinks, R.
    Genz, J.
    Giani, G.
    DIABETOLOGE, 2011, 7 (02): : 92 - 98
  • [6] Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: A systematic review
    Rinaldi, Giulia
    Hijazi, Alexa
    Haghparast-Bidgoli, Hassan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [7] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsapas, Apostolos
    Kourlaba, Georgia
    Papageorgiou, Giannis
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 417 - 426
  • [8] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Apostolos Tsapas
    Georgia Kourlaba
    Giannis Papageorgiou
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 417 - 426
  • [9] COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
    Gourzoulidis, G.
    Tzanetakos, C.
    Ioannidis, I.
    Tsapas, A.
    Kourlaba, G.
    Papageorgiou, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [10] Cost-effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance
    Ikeda, Shunya
    Kobayashi, Makoto
    Tajima, Naoko
    JOURNAL OF DIABETES INVESTIGATION, 2010, 1 (06) : 252 - 258